Switching From Intravenous to Subcutaneous Infliximab in Adult Patients With Inflammatory Bowel Disease

NAEnrolling by invitationINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 12, 2024

Primary Completion Date

May 1, 2025

Study Completion Date

May 1, 2025

Conditions

IBDInfliximabCrohn DiseaseUlcerative Colitis

Interventions

OTHER

Switch to SC CT-P13.

all patients in the study will switch from IFX to SC CT-P13

Trial Locations (1)

Zuyderland Medical Centre, Sittard

All Listed Sponsors

lead

Zuyderland Medisch Centrum

OTHER